好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

To Stay or To Go? Utilization of a Mobile Interventional Stroke Team Shortens Time to Treatment in Large Vessel Occlusion
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
3-021

Compare outcomes of mechanical thrombectomy (MT) in patients with large vessel occlusion (LVO) presenting to a single primary stroke center (PSC), when performed either by a mobile interventional stroke team (MIST) on site or after interhospital transfer to a comprehensive stroke center (CSC).

MT has become standard of care in acute LVO. Most hospitals cannot perform MT on site, requiring patient transfer to a CSC. Within a metropolitan multihospital healthcare system, utilization of a MIST shortens time to intervention, potentially resulting in better outcomes and decreased cost of care.  

We selected patients with acute LVO presenting to a PSC in Manhattan, NY, from 09/2013 to 02/2018, who underwent MT on site or after transfer to a CSC. Outcomes were assessed by Thrombolysis in Cerebral Infarction (TICI), NIH Stroke Scale (NIHSS), and modified Rankin Scale (mRS) scores.

One endovascular team performed 48 MTs; 37 patients were selected for analysis. 28 MTs were performed on site (group 1) and 9 after transfer (group 2). Median age was 74.5 and 73 years respectively. In group 1, median NIHSS and Alberta Stroke Program Early CT Score (ASPECTS) on presentation were 18 and 9, compared to 17 and 10 in group 2. Median door-to-puncture (DTP) time was 144.5 and 233 minutes respectively (p<0.05). In group 1, 82% had baseline mRS 0-2, compared to 36% at 90 days. In group 2, 100% had baseline mRS 0-2, and 22% at 90 days. TICI ≥2B was achieved in 89% in both groups, with complete reperfusion (TICI 3) in 50% and 11% respectively.

DTP times were significantly shorter in patients treated by a MIST. This group also had higher reperfusion grades and rates of functional independence, although statistical significance was not reached. Our data indicates that utilization of a MIST may be associated with better outcomes in acute LVO.

Authors/Disclosures
Lili Velickovic Ostojic, MD (Icahn School of Medicine at Mount Sinai)
PRESENTER
No disclosure on file
Maryna Skliut, MD Dr. Skliut has nothing to disclose.
Johanna T. Fifi, MD, FAAN (Mount Sinai Hospital) Dr. Fifi has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Stryker, Inc. Dr. Fifi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Microvention. Dr. Fifi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Fifi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Fifi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Serenity. Dr. Fifi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MIVI. Dr. Fifi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Fifi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. Dr. Fifi has stock in Endostream. Dr. Fifi has stock in Synchron. Dr. Fifi has stock in Imperative Care. Dr. Fifi has stock in Truvic. Dr. Fifi has stock in Bendit. Dr. Fifi has stock in Cerebrotech. Dr. Fifi has stock in Sim&Cure. Dr. Fifi has stock in Q'Apel. The institution of Dr. Fifi has received research support from Viz AI.